Literature DB >> 23475725

Noncovalent mass spectrometry for the characterization of antibody/antigen complexes.

Cédric Atmanene1, Elsa Wagner-Rousset, Nathalie Corvaïa, Alain Van Dorsselaer, Alain Beck, Sarah Sanglier-Cianférani.   

Abstract

Monoclonal antibodies (mAbs) have taken on an increasing importance for the treatment of various diseases including cancers, immunological disorders, and other pathologies. These large biomolecules display specific structural features, which affect their efficiency and need therefore to be extensively characterized using sensitive and orthogonal analytical techniques. Among them, mass spectrometry (MS) has become the method of choice to study mAb amino acid sequences as well as their posttranslational modifications with the aim of reducing their chemistry, manufacturing, and control liabilities. This chapter will provide the reader with a description of the general approach allowing antibody/antigen systems to be characterized by noncovalent MS. In the present chapter, we describe how recent noncovalent MS technologies are used to characterize immune complexes involving both murine and humanized mAb 6F4 directed against human JAM-A, a newly identified antigenic protein (Ag) over-expressed in tumor cells. We will detail experimental conditions (sample preparation, optimization of instrumental parameters, etc.) required for the detection of noncovalent antibody/antigen complexes by MS. We will then focus on the type and the reliability of the information that we get from noncovalent MS data, with emphasis on the determination of the stoichiometry of antibody/antigen systems. Noncovalent MS appears as an additional supporting technique for therapeutic mAbs lead characterization and development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23475725     DOI: 10.1007/978-1-62703-327-5_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  Interpretation and deconvolution of nanodisc native mass spectra.

Authors:  Michael T Marty; Hao Zhang; Weidong Cui; Michael L Gross; Stephen G Sligar
Journal:  J Am Soc Mass Spectrom       Date:  2013-12-19       Impact factor: 3.109

Review 2.  Posttranslational Modifications and the Immunogenicity of Biotherapeutics.

Authors:  Roy Jefferis
Journal:  J Immunol Res       Date:  2016-04-14       Impact factor: 4.818

3.  Native mass spectrometry combined with enzymatic dissection unravels glycoform heterogeneity of biopharmaceuticals.

Authors:  Therese Wohlschlager; Kai Scheffler; Ines C Forstenlehner; Wolfgang Skala; Stefan Senn; Eugen Damoc; Johann Holzmann; Christian G Huber
Journal:  Nat Commun       Date:  2018-04-30       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.